Posts Tagged ‘pharmaceutical industry’

Pharma Generosity: Who Donates the Most?

Tuesday, June 29th, 2010

According to the Financial Times, Glaxo donates the most medication to the poor. Merck was in second place and Novartis in third place. The article noted that most Eurpoean companies ranked above their US-based peers. In 11th (last) place was the only Japanese company listed- Daiichi Sanyko.

One advantage cited in the article to donating medications is positioning a company to succeed in emerging markets. As noted earlier this year in BioPharma Pulse, emerging markets are the expected growth areas for the future. Pharma companies may want to consider their overall profile in emerging markets and identify ways to raise their profile. These tactics will likely vary by country as marketing has moved to increased personalization and away from one-sized fits all. Increasing donations may not only raise a company’s profile, but also strengthen the humanity of the donors as well as alleviate suffering.

Pharmaceutical Drug Sales Outlook Mixed

Wednesday, April 21st, 2010

IMS Health released data today indicating that pharmaceutical drug sales growth will slow globally to between 4% and 6% down from 7% last year. Generic drugs and patent expirations will continue to pressure brand drugs.

However, drug sales globally are expected to be up for 2010, growing 5% worldwide. Much of the growth is expected to come from China and India. One challenge for leading biopharma companies will be the large amount of fake drugs in these countries as well as established generic competitors. Successful branded biopharma products need a solid reputation for safety and superiority if consumers are to be expected to pay substantially more for them.

IMS Health predicts that the top disease therapy growth areas will be: diabetes, cancer, HIV, and multiple sclerosis.

http://bit.ly/Pharma_Forecast_2010

http://bit.ly/Drug_Sales_2010

Lessons from the DIA Marketing Pharmaceuticals in a Time of Change Conference

Friday, February 27th, 2009

After two intensive days, I’m at the DIA Marketing Pharmaceuticals in a Time of Change conference, I’m back in the office and reflecting on lessons learned. The overwhelming sentiment this year was that “time of change” was a serious understatement.

Continuing medical education is undergoing revolutionary change unprecedented in the history of the field due to intense environmental and political pressure. Numerous companies will or have voluntarily or involuntarily exited the field and consolidation can be expected to continue until a new equilibrium is reached.

Overall the pharmaceutical industry is being buffeted by the same political and economic changes that are affecting other industries. Because the pharmaceutical industry had already been preparing for change (due to loss of cash cow products) and because healthcare products are necessities the industry is likely to fare somewhat better than others.

However, regulations on both the state and federal level are changing rapidly requiring companies to invest money and manpower in keeping on top of current requirements. In addition, technological changes are altering long held marketing strategies forcing companies to wade into untested waters just at the time the regulations are in flux and legal penalties are high for transgressions.

This year won’t be for the faint of heart but for those who enjoy challenges, there will be an abundance to choose from.

BioPharma on the Rise

Thursday, February 5th, 2009

When I founded Hughes BioPharma Advisers in 2005, the term biopharma was used infrequently. I sometimes got blank stares or queries like, “What is biopharma anyway?”.

Now with the purchase of Wyeth by Pfizer and the pending sale of Genentech to Roche, biopharma is ascending. The large pharmaceutical companies are looking more than ever to biotech companies for creative new products. What’s even more exciting is that these biotech companies aren’t simply being engulfed but are changing the whole perspective of large pharma companies. Biotech products are being looked at as the future of the industry.

Small molecule pharmaceutical products aren’t going to go away but we can expect to see a blending of them in product portfolios.

This change will be good for both the pharma and biotech industries as well as for patients. Pharma companies have the cash to purchase biotech companies. Biotech companies are in desperate need of funding. Selling to a pharma company keeps their products in the pipeline. Patients benefit by having more and, hopefully, better treatment choices.

The future of pharma looks more and more like biopharma.

Welcome to the Pharma Future Network!

Saturday, November 15th, 2008

This blog will offer trend analysis and discussion on the future of the pharmaceutical and biotechnology industries. Future posts will include industry trend discussion from guest bloggers.

The remainder of 2008 and well into 2009 looks like it offers many challenges. Tune into the pharma future network as you plan strategic moves for your company or your career.